44 reports

  • PRODUCT PROFILE - ENCORAFENIB +BINIMETINIB

NY-ESO-## IS A CANCER ANTIGEN EXPRESSED IN A VARIETY OF CANCERS, INCLUDING COLORECTAL, RENAL AND ESOPHAGEAL.

  • Colorectal Cancer
  • Product Initiative
  • Merck & Co., Inc.
  • Roche Group
  • Taiho Pharmaceutical Co., Ltd.

Colorectal cancer

4385 5000 3900
  • Colorectal cancer Disease Coverage | Pipeline: Colorectal Cancer
  • STIVARGA FOR COLORECTAL CANCER - SWOT ANALYSIS

TS-## FORECAST, 2015-## FIGURE ##: TS-## SALES FOR COLORECTAL CANCER IN JAPAN ($M), 2015-## TABLE ##: TS-## SALES FOR COLORECTAL CANCER IN JAPAN ($M), 2015-## The table below shows Datamonitor Healthcare' s forecast of the total number

  • Colorectal Cancer
  • European Union
  • North America
  • United States
  • Product Initiative
  • COLORECTAL CANCER
  • COLORECTAL CANCER

COLORECTAL CANCER COLORECTAL CANCER COLORECTAL CANCER METASTATIC COLORECTAL CANCER PRECLINICAL COLORECTAL CANCER COLORECTAL CANCER COLORECTAL CANCER COLORECTAL

  • Colorectal Cancer
  • Pharmaceutical
  • Targeted Therapy
  • Product Initiative
  • Merck & Co., Inc.

Colorectal Cancer Pipeline Highlights – 2017 ##.

  • Cancer
  • Colorectal Cancer
  • United States
  • Product Initiative
  • Products under Investigation by Universities/Institutes, H1 2019
  • Number of Products under Development by Indication, H1 2019

One of these trials was Jun ##, 2018: Exploring a New Treatment for Metastatic Colorectal Cancer completed at Rutgers Cancer Institute in patients with pancreatic cancer.

  • Colorectal Cancer
  • Medical Biotechnology
  • Monoclonal Antibody
  • Product Initiative
  • Etubics Corporation
  • Metastatic Colorectal Cancer
  • Products under Investigation by Universities/Institutes, H2 2018

One group will receive nivolumab and the standard chemotherapy given for colorectal cancer that has spread to the liver in addition to surgery.

  • Colorectal Cancer
  • Monoclonal Antibody
  • Pharmaceutical
  • Product Initiative
  • Etubics Corporation
  • Products under Development by Companies, H2 2018 (Contd..1), H2 2018
  • Products under Development by Companies, H2 2018

It was also under development for the treatment of choroidal neovascularization, proliferative vitreoretinopathy (PVR), hematological cancer, colorectal cancer (third line therapy) and metastatic colorectal cancer (first line therapy).

  • Biopharmaceutical
  • Colorectal Cancer
  • United States
  • World
  • Product Initiative
  • free survival (PFS), overall survival (OS) and duration of response.
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATIONS, H1 2019

One group will receive nivolumab and the standard chemotherapy given for colorectal cancer that has spread to the liver in addition to surgery.

  • Colorectal Cancer
  • Immunotherapy
  • Therapy
  • Vaccine
  • Product Initiative
  • Metastatic Colorectal Cancer - Dormant Projects
  • Metastatic Colorectal Cancer - Discontinued Products

Qualified subjects, who have KRAS WT colorectal cancer will be randomized in a ##:## ratio to either: Arm ## which contains Imprime PGG and cetuximab or Arm ## containing cetuximab.

  • Colorectal Cancer
  • Monoclonal Antibody
  • Targeted Therapy
  • Therapy
  • Product Initiative
  • SMALL MOLECULES TO AGONIZE DR4 AND DR5 FOR COLORECTAL CANCER - DRUG PROFILE
  • PIPELINE BY ABBVIE INC, H1 2018

THE PHASE ## TRIAL IN COLORECTAL CANCER IS ONGOING, WITH A PRESENTATION OF THE RESULTS ANTICIPATED ON NOVEMBER ## AT THE 2005 EUROPEAN CANCER CONFERENCE (ECCO).

  • Colorectal Cancer
  • Hospital
  • Medical Biotechnology
  • Product Initiative
  • GlaxoSmithKline plc

Two patients with PI##KCA H##R mutant breast cancers have ongoing RECIST partial response; ## patient with PIK##CA E##K colorectal cancer had stable disease for ## weeks.

  • Breast Cancer
  • Colorectal Cancer
  • United States
  • Product Initiative
  • Pfizer Inc.

It was also under development for colorectal cancer.

  • Colorectal Cancer
  • Lymphoma
  • United States
  • Product Initiative
  • Merck & Co., Inc.

THIS SYSTEM IS MAINLY USED IN DIAGNOSING COLORECTAL CANCER AND ALSO PLANS TO EXTEND ITS APPLICATION TO ESOPHAGEAL, BLADDER, LUNG AND OTHER CANCERS.

  • Biopsy
  • Clinical Trial
  • Colorectal Cancer
  • Product Initiative
  • SpectraScience, Inc.

Interleukin ## Alpha (IL ## Alpha or Hematopoietin ## or IL##A) - Pipeline Review, H## 2016 GMDHC##TDB / Pub December 2016 advanced colorectal cancer (CRC).

  • Colorectal Cancer
  • Pharmaceutical
  • Europe
  • Product Initiative
  • XBiotech Inc.
  • PIPELINE BY ENTRECHEM SL, H2 2018
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATION, H2 2018

The prognosis of colorectal cancer is poor due to the limited therapeutic options and the lack of specific targeted agents.

  • Colorectal Cancer
  • Targeted Therapy
  • World
  • Product Initiative
  • IMMD
  • IO Marketed Product Lifecycle Development in Colorectal Cancer
  • OF CONTENTS (2/4)

Colorectal cancer ##.

  • Clinical Trial
  • Colorectal Cancer
  • Epidemiology
  • Therapy
  • Product Initiative
  • Clinical Trial profile. 147 Trial Title
  • Clinical Trial profile. 38 Trial Title

Falk Pharma GmbH ## Jul 2012 ## Jun 2015 ## ## ## ## Prostaglandin G/ H Synthase (Cyclooxygenase or COX or PTGS or EC ##. ##. ##. ##) Inhibitor Prostaglandin G/ H Synthase (Cyclooxygenase or COX or PTGS or EC ##. ##. ##. ##) Pilot Trial on Efficacy of Single Dose Perioperative Intraven

  • Colorectal Cancer
  • Therapy
  • World
  • Product Initiative
  • Novartis AG
  • PIPELINE BY ENTRECHEM SL, H1 2018
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATION, H1 2018

The prognosis of colorectal cancer is poor due to the limited therapeutic options and the lack of specific targeted agents.

  • Brain Cancer
  • Colorectal Cancer
  • World
  • Product Initiative
  • IMMD
  • EMI-137 - Product Description

Cancer ## Lung Disease ## Lung Fibrosis ## Nodules ## Oral Squamous Cell Carcinoma ## Pancreatic Cancer ## Prostate Cancer ## Thyroid Cancer ## Colorectal Cancer ## Gastric Cancer

  • Colorectal Cancer
  • Diagnostic Imaging
  • Nuclear Imaging Equipment
  • United Kingdom
  • Product Initiative
  • Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018
  • Products under Development by Companies, H1 2018

" We saw promising indications of efficacy in metastatic colorectal cancer patients in our phase ##/ ##a clinical study of apatinib, " noted Dr.

  • Cancer
  • Colorectal Cancer
  • Targeted Therapy
  • Therapy
  • Product Initiative
  • XILONIX - DRUG PROFILE

Every year approximately ##, ## people are diagnosed with colorectal cancer in Europe and half this number will not survive. ## Colorectal cancer is currently the second leading cause of cancer death in Europe##, and the incidence of

  • Colorectal Cancer
  • Medical Biotechnology
  • Therapy
  • Product Initiative
  • XBiotech Inc.
  • SMALL MOLECULES TO AGONIZE DR4 AND DR5 FOR COLORECTAL CANCER - DRUG PROFILE
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H2 2017 (CONTD..1), H2 2017

THE PHASE ## TRIAL IN COLORECTAL CANCER IS ONGOING, WITH A PRESENTATION OF THE RESULTS ANTICIPATED ON NOVEMBER ## AT THE 2005 EUROPEAN CANCER CONFERENCE (ECCO).

  • Colorectal Cancer
  • Hospital
  • Monoclonal Antibody
  • Therapy
  • Product Initiative

Drug analysis: Avastin

8770 10000 7800

The drug was first approved for colorectal cancer in 2004, and then went on to gain approvals for lung, brain, ovarian, cervical, and renal cell cancer indications.

  • Colorectal Cancer
  • European Union
  • Japan
  • United States
  • Product Initiative

Two late-stage, pivotal Phase III registration studies are ongoing in colorectal cancer (FRESCO) and lung cancer (FALUCA).

  • Colorectal Cancer
  • Pharmaceutical
  • Targeted Therapy
  • Product Initiative
  • Hutchison MediPharma Limited
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATION, H2 2018
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H2 2018

It is in Phase II stage of development for microsatellite stable relapsed or refractory colorectal cancer.

  • Colorectal Cancer
  • Lymphoma
  • Therapy
  • Product Initiative
  • eFFECTOR Therapeutics, Inc.

Cancer ## Colorectal Cancer ## Gastric Cancer ## Breast Cancer ## Cancer ## Ovarian Cancer ## Pancreatic Cancer ## Indication No of Products Guardant Health Inc - Pipeline Analysis Overview

  • Colorectal Cancer
  • Genetic Testing
  • Hospital
  • Product Initiative
  • Guardant Health, Inc.

Researchers reported that they have investigated the in vivo efficacy of COTI-## in ## tumor xenograft models in mice, such as HT-## colorectal cancer, SHP-## SCLC, U##-MG glioblastoma, MDA- MB-## breast cancer, and OVCAR-## ovarian cancer.

  • Colorectal Cancer
  • United States
  • World
  • Product Initiative
  • Critical Outcome Technologies Inc.
  • Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Dormant Products

It was also under development for the treatment of advanced colorectal cancer, non-small cell lung cancer, relapsed or refractory Hodgkin' s lymphoma, advanced hepatocellular carcinoma and other solid tumors.

  • Cancer
  • Colorectal Cancer
  • Pharmaceutical
  • Therapy
  • Product Initiative
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATION, H2 2018
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H2 2018

THE DRUG CANDIDATE IS IN PHASE II STAGE OF DEVELOPMENT FOR MICROSATELLITE STABLE RELAPSED OR REFRACTORY COLORECTAL CANCER.

  • Colorectal Cancer
  • Lymphoma
  • Therapy
  • Product Initiative
  • eFFECTOR Therapeutics, Inc.
  • Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Dormant Products

It was also under development for the treatment of advanced colorectal cancer, non-small cell lung cancer, relapsed or refractory Hodgkin' s lymphoma, advanced hepatocellular carcinoma and other solid tumors.

  • Cancer
  • Colorectal Cancer
  • Pharmaceutical
  • Therapy
  • Product Initiative